Sipuleucel-T
Sipuleucel-T, known by its trade name Provenge, is a therapeutic cancer vaccine specifically formulated for the treatment of prostate cancer. Manufactured by Dendreon Corporation, Sipuleucel-T represents a groundbreaking approach in cancer therapy. Unlike traditional vaccines that aim to prevent diseases, therapeutic vaccines like Provenge treat existing diseases.
Background[edit | edit source]
- Trade Name: Provenge
- Generic Name: Sipuleucel-T
- Manufacturer: Dendreon Corporation
Mechanism of Action[edit | edit source]
Sipuleucel-T is designed to stimulate the body's immune system to target and attack cancer cells. The vaccine is prepared by isolating immune cells from the patient, exposing them to a protein found on prostate cancer cells, and then reintroducing them into the patient. This process enhances the immune cells' ability to recognize and combat prostate cancer.
Indications[edit | edit source]
- Primary Indication: Prostate cancer, specifically for the treatment of metastatic castration-resistant prostate cancer (mCRPC).
Preparation[edit | edit source]
One of the unique features of Sipuleucel-T is that it must be custom-made for each individual patient. The process involves:
- Extracting a sample of the patient's blood.
- Processing the blood to isolate specific immune cells, known as antigen-presenting cells (APCs).
- Exposing the APCs to a prostate cancer antigen, causing them to activate.
- Reinfusing the activated APCs back into the patient.
Clinical Trials and Efficacy[edit | edit source]
The efficacy of Sipuleucel-T was most notably demonstrated in the IMPACT Phase III clinical trial. Key findings from the trial include:
- An extension of median survival by 4.1 months for patients with metastatic prostate cancer.
- Well-tolerated with a favorable safety profile.
Side Effects[edit | edit source]
As with any therapeutic intervention, Sipuleucel-T may have side effects, including:
- Fever
- Chills
- Fatigue
- Joint pain
- Nausea
It's crucial to consult with healthcare professionals about potential side effects and to monitor any reactions after administration.
Cost and Reimbursement[edit | edit source]
Given the personalized nature of the treatment, Sipuleucel-T is notably expensive. However, many insurance providers cover the treatment, and assistance programs are available for eligible patients. Sipuleucel-T treatment consists of three infusions at approximately two-week intervals for one month. The cost for a complete course of treatment of three infusions is $93,000, which includes the cost of administration.
Conclusion[edit | edit source]
Sipuleucel-T (Provenge) has emerged as a significant advancement in the fight against prostate cancer, offering a novel treatment approach that harnesses the power of the immune system. While its use and benefits are specific, the drug represents the potential of immunotherapy in cancer treatment.
Note: This article provides a comprehensive overview of Sipuleucel-T. Patients should consult with oncologists or urologists for detailed medical advice and information tailored to individual circumstances.
External links[edit | edit source]
- Official website
- "Provenge (sipuleucel-T)". FDA Vaccines, Blood & Biologics.
- "Provenge Package Insert and Patient Information". FDA.
- "Provenge". Daily Med.
Navigation: Wellness - Encyclopedia - Health topics - Disease Index - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro) available.
Advertise on WikiMD
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.Contributors: Prab R. Tumpati, MD